Drugs / NY-ESO-1-specific T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01477021 | Jan 2012 → Sep 2013 | adult liposarcoma, synovial sarcoma | Fred Hutchinson Cancer Center | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NY-ESO-1-specific T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01477021 ↗ |
| Modality | Cell therapy | “cellular adoptive immunotherapy” NCT01477021 ↗ |
| Route | Intravenous | “Patients receive NY-ESO-1-specific T cells IV on day 0.” NCT01477021 ↗ |